Utah Medical Products, Inc.
NASDAQ:UTMDMedical - Instruments & Supplies
+$1.10 today
- Market cap
- $205.81M
- Beta
- 0.37
- P/E (TTM)
- 19.6
- EPS (TTM)
- $3.41
- Dividend yield
- 1.85%
Volume 0.02M
Average 0.01M
UTMD Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Utah Medical Products, Inc.NASDAQ: UTMD
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue dips below year-ago levels
Q1 FY2026 cost of revenue of $3.44M fell 17.5% year over year, behind the +0.1% change in trailing-twelve-month cost of revenue. Sequentially, it fell 20.2% from the prior quarter. Over 3 fiscal years it compounded at -2.4% a year.
Context
- Cost of revenue amounted to 48.4% of revenue in FY2025, up 7.4 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -17.5% toward the trailing-twelve-month pace of +0.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 18.65M USD
- Year-over-year change
- +11.2%
- 4-year CAGR
- +0.7%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.65M | +11.2% |
| FY2024 | 2024-12-31 | 16.76M | -17.0% |
| FY2023 | 2023-12-31 | 20.19M | +0.5% |
| FY2022 | 2022-12-31 | 20.09M | +10.7% |
| FY2021 | 2021-12-31 | 18.14M | — |
Cost of Revenue vs competitors
How UTMD compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +0.1% is the 6th highest of 10, against a peer median of +17.1%.
- Cost of revenue amounts to 46.4% of revenue for UTMD, versus a peer median of 42.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.91M USD | +141.8% | +70.6% | 52.0% | |
| LTM Mar 2026 | $66.66M USD | -28.2% | -34.6% | 59.0% | |
| LTM Mar 2026 | $61.59M USD | -4.5% | +8.6% | 43.3% | |
| LTM Mar 2026 | $47.41M USD | +110.1% | +65.9% | 41.7% | |
| LTM Mar 2026 | $22.94M USD | -23.3% | +12.0% | 30.0% | |
| LTM Mar 2026 | $18.73M USD | -78.7% | -36.7% | 40.0% | |
| LTM Mar 2026 | $17.4M USD | +0.1% | -2.4% | 46.4% | |
| LTM Mar 2026 | $16.67M USD | +30.1% | +7.4% | 38.5% | |
| LTM Mar 2026 | €8.43M EUR | +460.5% | +47.5% | 51.7% | |
| LTM Mar 2026 | $5.46M USD | +17.1% | +9.4% | 28.9% | |
| LTM Mar 2026 | $2.63M USD | — | — | 426.2% | |
| Peer median (excluding UTMD) | — | +17.1% | +9.4% | 42.5% | |
Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 49.05M | 52.28M | 50.22M | 40.9M | 38.52M |
| Cost of Revenue | 18.14M | 20.09M | 20.19M | 16.76M | 18.65M |
| Gross Profit | 30.92M | 32.2M | 30.04M | 24.14M | 19.88M |
| Gross Margin | 63.0% | 61.6% | 59.8% | 59.0% | 51.6% |
| Research & Development | 526K | 493K | 560K | 813K | 668K |
| Selling, General & Admin | 11.51M | 11.91M | 12.7M | 5.57M | 7.81M |
| Operating Expenses | 12.04M | 12.41M | 13.26M | 10.55M | 8.47M |
| Depreciation & Amortization | 7.28M | 7.08M | 6.37M | 2.77M | 2.95M |
| EBITDA | 26.35M | 27.74M | 24.75M | 19.57M | 17.06M |
| EBITDA Margin | 53.7% | 53.1% | 49.3% | 47.9% | 44.3% |
| Operating Income | 18.88M | 19.79M | 16.78M | 13.59M | 11.4M |
| Operating Margin | 38.5% | 37.9% | 33.4% | 33.2% | 29.6% |
| Interest Income | 166K | 661K | 0 | 3.37M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 181K | 869K | 3.31M | 3.21M | 2.71M |
| Income Before Tax | 19.06M | 20.66M | 20.09M | 16.8M | 14.11M |
| Pre-Tax Margin | 38.9% | 39.5% | 40.0% | 41.1% | 36.6% |
| Income Tax Expense | 4.27M | 4.19M | 3.45M | 2.93M | 2.82M |
| Net Income | 14.79M | 16.47M | 16.64M | 13.87M | 11.29M |
| Net Margin | 30.1% | 31.5% | 33.1% | 33.9% | 29.3% |
| EPS (Basic) | 4.05 | 4.53 | 4.57 | 3.96 | 3.41 |
| EPS (Diluted) | 4.04 | 4.52 | 4.57 | 3.96 | 3.48 |
| Weighted Avg Shares | 3.65M | 3.64M | 3.64M | 3.5M | 3.31M |
| Weighted Avg Shares (Diluted) | 3.66M | 3.64M | 3.64M | 3.5M | 3.24M |
Utah Medical Products, Inc.
NASDAQ:UTMD
Intrinsic Alpha fair value
Locked
Current Price
$72.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.